MBX Biosciences is trading at $51.60, down 4.32%, with broad market weakness the likeliest context; no clear company-specific catalyst was identified. - Supplied market context shows substantial declines in the S&P 500 and Nasdaq, consistent with broad risk-off pressure. - A Reuters-sourced report published at 1:24 p.m. announced Peter Radovich’s board appointment, after the 12:57 p.m. snapshot, so it does not explain the decline at that time.